Global Pertussis Treatment Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

Pertussis Treatment Market Analysis

The pertussis treatment market is driven by the increasing prevalence of whooping cough globally, with a growing demand for vaccines, antibiotics, and other therapies to combat the disease. Pertussis, a highly contagious respiratory illness, primarily affects infants and young children, though it can impact individuals of all ages. The market is influenced by factors such as advancements in vaccine development, government vaccination programs, and rising awareness about early diagnosis and treatment. Recent developments include improved vaccine formulations and the introduction of newer antibiotic treatments aimed at reducing the severity of symptoms and preventing complications. Pharmaceutical companies are focusing on innovation and expanding their product portfolios, while increased research on combination vaccines is also shaping market growth. The increasing focus on public health initiatives, combined with the emergence of novel treatment options, is expected to support market expansion in the coming years.

Pertussis Treatment Market Size

The global pertussis treatment market size was valued at USD 3.80 billion in 2024 and is projected to reach USD 6.24 billion by 2032, with a CAGR of 6.40% during the forecast period of 2025 to 2032. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Pertussis Treatment Market Trends

“Development of Combination Vaccines”

由于百日咳发病率不断上升，以及对有效预防和治疗的重视程度不断提高，百日咳治疗市场正在经历显著增长。随着疫苗配方和抗生素疗法的进步，市场也在不断发展。一个关键趋势是开发可预防多种疾病（包括百日咳）的联合疫苗，这提高了疫苗接种率并降低了治疗成本。此外，抗生素治疗的创新旨在减轻症状的严重程度并预防并发症，支持早期干预。提高对百日咳预防的认识和改进诊断工具的关注进一步推动了市场需求。总体而言，随着政府和医疗保健提供者优先考虑有效的百日咳控制策略，市场正在扩大。

报告范围和百日咳治疗市场细分

百日咳治疗市场定义

百日咳，又称百日咳，是一种由百日咳杆菌引起的高度传染性呼吸道疾病。其特征是剧烈咳嗽，呼吸困难，深吸气时常发出“呼呼”声。该病主要影响婴幼儿，也影响青少年和成年人。百日咳通过感染者咳嗽或打喷嚏时的呼吸道飞沫传播。早期症状类似于普通感冒，如流鼻涕、打喷嚏和轻微咳嗽，但这些症状会发展为严重的咳嗽发作。

百日咳治疗市场动态

驱动程序

• 百日咳发病率上升

百日咳发病率不断上升，尤其是在婴幼儿中，这是百日咳治疗市场的重要推动力。婴儿最容易受到百日咳严重并发症的影响，通常需要立即接受医疗干预。全球报告病例数不断增加，这加剧了对有效治疗方案的需求，包括抗生素和支持性护理。病例激增促使医疗保健提供者和政府专注于改善诊断、预防和治疗策略。随着该疾病继续影响年轻人口，对治疗方案和疫苗接种工作的需求不断增长，进一步推动了市场增长。

• 改进抗生素疗法

开发更有效的百日咳抗生素和治疗方法是百日咳治疗市场增长的关键驱动力。阿奇霉素和克拉霉素等新型抗生素在降低疾病严重程度和持续时间方面表现出更大的功效，尤其是早期使用时。这些进步有助于预防并发症、最大限度地降低传播风险并提高康复率，尤其是对于婴儿等脆弱人群。随着医学界不断发展和推出更好的治疗方案，对这些治疗的需求正在增加。这支持更好的患者治疗结果，有助于百日咳治疗市场的整体扩张。

机会

• 疫苗接种计划的进展

全球范围内，尤其是在新兴市场，扩大疫苗接种计划的努力为百日咳治疗市场的增长提供了巨大的机会。随着越来越多的国家投资于抗击百日咳的免疫接种运动，对预防和治疗方案的需求也在增加。这些举措提高了疫苗接种覆盖率，提高了人们对该疾病的认识，从而实现了早期诊断和治疗。在医疗基础设施不断改善的新兴市场中，除了疫苗接种外，对有效治疗方案（包括抗生素和支持性护理）的需求也日益增长。这种预防和治疗的双重方法预计将推动整体市场需求和扩张。

• 先进诊断工具的兴起

百日咳早期检测方法的兴起为市场参与者创新和开发先进诊断工具提供了重要机会。随着医疗保健系统越来越注重及时诊断以防止百日咳传播，对快速、准确诊断解决方案的需求也在增长。这些创新，例如基于 PCR 的测试和分子诊断试剂盒，可以早期识别疾病，从而及时治疗并改善患者预后。通过将这些诊断工具与现有的治疗解决方案相结合，公司可以提供全面的护理方案，改善整体疾病管理。这种整合代表着一个有希望的市场机会，特别是在百日咳病例不断​​增加的地区。

限制/挑战

• 全球健康差距

医疗保健服务可及性的差异，尤其是在发展中国家，对百日咳治疗市场构成了重大挑战。在许多低收入地区，医疗保健基础设施有限、缺乏训练有素的医疗专业人员以及免疫计划资金不足，阻碍了百日咳疫苗和有效治疗方案的广泛传播。这些差异导致诊断和治疗延迟，导致发病率和死亡率上升。此外，这些地区的医疗保健和药物成本高昂，使许多人无法获得必要的治疗。因此，这些挑战限制了百日咳治疗的整体市场潜力，特别是在服务不足的新兴市场。

•  治疗费用高昂

在某些地区，百日咳治疗（包括疫苗和抗生素）的高成本是市场发展的一大制约因素。在医疗预算有限的低收入和新兴市场，预防和治疗方案的成本对于很大一部分人口来说都过于高昂。这种经济障碍导致疫苗接种率低、治疗延误或治疗不足，阻碍了控制百日咳传播的努力。因此，这些地区的市场采用速度放缓，限制了百日咳治疗的广泛使用潜力，并延缓了发展中经济体的整体市场增长。

本市场报告详细介绍了最新发展、贸易法规、进出口分析、生产分析、价值链优化、市场份额、国内和本地市场参与者的影响，分析了新兴收入领域的机会、市场法规的变化、战略市场增长分析、市场规模、类别市场增长、应用领域和主导地位、产品批准、产品发布、地域扩展、市场技术创新。如需获取更多市场信息，请联系 Data Bridge Market Research 获取分析师简报，我们的团队将帮助您做出明智的市场决策，实现市场增长。

百日咳治疗市场范围

市场根据产品、类型、诊断、治疗、药物、给药途径、应用、最终用户和分销渠道进行细分。这些细分市场之间的增长将帮助您分析行业中增长微弱的细分市场，并为用户提供有价值的市场概览和市场洞察，帮助他们做出战略决策，确定核心市场应用。

产品

• 全细胞疫苗
• 无细胞疫苗
• 其他的

类型

• 阿奇霉素
• 克拉霉素
• 红霉素
• 其他

诊断

• 胸部 X 光检查
• 血液检查
• 其他的

治疗

• 药物
• 疫苗接种
• 其他的

药物

• 抗生素
• 止咳药
• 其他的

给药途径

• 口服
• 注射剂
• 其他的

应用

• 孩子们
• 成年人

最终用户

• 医院
• 家庭护理
• 专科诊所
• 其他的

分销渠道

• 医院药房
• 网上药店
• 零售药店
• 其他的

百日咳治疗市场区域分析

对市场进行分析，并按国家、产品、类型、诊断、治疗、药物、给药途径、应用、最终用户和上述分销渠道提供市场规模洞察和趋势。

市场报告涉及的国家包括北美洲的美国、加拿大和墨西哥、欧洲的德国、法国、英国、荷兰、瑞士、比利时、俄罗斯、意大利、西班牙、土耳其、欧洲其他地区、亚太地区（APAC）的中国、日本、印度、韩国、新加坡、马来西亚、澳大利亚、泰国、印度尼西亚、菲律宾、亚太地区（APAC）的其他地区、沙特阿拉伯、阿联酋、南非、埃及、以色列、中东和非洲（MEA）的其他地区、南美洲的巴西、阿根廷和南美洲其他地区。

North America leads the pertussis treatment market, driven by a rising demand for treatments targeting newborns and infants. The region's high healthcare expenditure enables access to advanced treatment options, further supporting market growth. Additionally, strong government initiatives focused on providing reliable healthcare solutions play a crucial role in boosting the demand for pertussis treatments.

Europe is expected to experience notable growth in the pertussis treatment market, driven by its substantial share of the global economy. The region’s rapidly improving healthcare infrastructure is enhancing access to advanced treatments and vaccination programs. Additionally, strong economic development in many European countries supports increased investment in public health initiatives, further contributing to market growth.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.  

Pertussis Treatment Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

Pertussis Treatment Market Leaders Operating in the Market Are:

• Sanofi (France)
• Takeda Pharmaceutical Company Limited (Japan)
• Biological E Limited (India)
• Astellas Pharma Inc. (Japan)
• Johnson & Johnson Services, Inc. (U.S.)
• Novartis AG (Switzerland)
• Merck & Co., Inc. (U.S.)
• GSK plc. (U.K.)
• Mitsubishi Tanabe Pharma Corporation (Japan)
• Pfizer Inc. (U.S.)
• F. Hoffmann-La Roche Ltd (Switzerland)
• Panacea Biotec (India)
• Serum Institute of India Pvt. Ltd. (India)
• Bharat Biotech (India)
• ILiAD Biotechnologies (U.S.)
• Eisai Co., Ltd. (Japan)

Latest Developments in Pertussis Treatment Market

• In February 2022, GlaxoSmithKline initiated a Phase III clinical trial to evaluate the safety and immune response of an unadjuvanted RSV maternal vaccine. The study focuses on healthy non-pregnant women aged 9 to 49 years. This investigation aims to assess the potential of the vaccine in preparing maternal immunity for the prevention of respiratory syncytial virus (RSV)
• In February 2021, GlaxoSmithKline began a Phase IV clinical trial to compare the safety and immunogenicity of MCM BV’s Vaxelis vaccine with its own Infanrix Hexa vaccine. The study targets healthy infants and toddlers aged 6 to 12 weeks. The goal is to assess the effectiveness and safety profiles of both vaccines when administered to young children
• In January 2021, Sanofi launched a Phase IV clinical trial in the Republic of South Africa to evaluate the immune response to booster vaccination with the Tdap-IPV vaccine, which protects against tetanus, diphtheria, pertussis, and poliomyelitis. The trial aims to assess the vaccine’s effectiveness in boosting immunity in individuals. This investigation is part of Sanofi's ongoing efforts to improve vaccination strategies and public health outcomes

SKU-50276